Your 2027 Pipeline Is Already Writing Your Hiring Plan

A practical way for biotech and pharmaceutical leaders to connect development milestones with the scientific capabilities they will need next

Workforce planning often begins with an org chart, a budget, and a familiar question: Which positions can we approve next year? For scientific teams, there is a more useful place to start. Look at the decisions the pipeline will need the organization to make in 2027, then work backward to the capabilities, capacity, and leadership required to make them well.

That shift matters in a selective hiring environment. The U.S. Bureau of Labor Statistics reported on October 2 that preliminary nonfarm payroll employment increased by 29,000 in September 2026, a change the agency described as little movement. In its September 8 Q4 Employment Outlook Survey, ManpowerGroup reported that 62 percent of employers planning to add staff cited changing roles and skills as the primary driver, rather than simply replacing like-for-like skills.

For biotech and pharmaceutical organizations, the message is not to hire broadly or to stop hiring. It is to make each talent decision traceable to the work ahead. A pipeline-based workforce plan helps leaders see which capabilities are enduring, which needs are time-bound, and when a search should begin to support an important development milestone.

Start with the decision calendar

A development plan is also a talent-demand forecast. Upcoming milestones create specific scientific questions, and those questions determine what expertise the organization must be able to access.

Consider the decisions your teams may need to support in the next 12 to 18 months:

• Selecting a first-in-human dose or refining a dosing strategy
• Connecting nonclinical findings with an early clinical development plan
• Evaluating exposure response or benefit-risk as data accumulate
• Preparing model-informed evidence for a regulatory interaction or submission
• Deciding whether to advance, redesign, partner, pause, or discontinue a program
• Integrating a new asset, modality, or external dataset into the portfolio

Each decision has a latest useful date. It also has an evidence standard and a set of people who must create, interpret, challenge, and communicate that evidence. Once those elements are visible, workforce planning becomes much more concrete than a list of desired positions.

Translate milestones into capabilities

The next step is to translate each milestone into capabilities rather than job titles. Titles vary considerably among organizations. A Director of Clinical Pharmacology may be a hands-on scientific lead in one company, a portfolio strategist in another, or the primary regulatory voice for the function in a third.

For every material pipeline decision, ask four questions:

Planning lens	Question to answer
Scientific work	What analysis, modeling, experimentation, or interpretation must be completed?
Decision ownership	Who must turn the evidence into a recommendation and explain the tradeoffs?
Cross functional work	Which partners must align across Clinical Development, Statistics, Regulatory, DMPK, Bioanalysis, or other functions?
Timing	When must the capability be in place and ready to contribute effectively?

Distinguish capacity needs from capability needs

These needs are easy to confuse, but they call for different forms of support. A capacity need arises when the organization has the relevant expertise but would benefit from more time or coverage. A capability need arises when additional experience, judgment, or technical depth would strengthen the team for the work ahead.

If the need is capacity, the answer may be clearer prioritization, additional execution support, or a time-bound external resource. If the team would benefit from a new capability, increasing staffing capacity alone may not address the requirement. The organization may consider a permanent hire, a senior scientific leader, or a partner who can provide expertise while internal capability continues to grow.

This distinction also improves the search itself. It helps hiring managers explain whether they need someone to perform the work, design the scientific strategy, lead regulatory discussions, build a function, develop others, or combine several of those responsibilities.

Choose the right way to add the capability

Once the need is clear, leaders can make a more deliberate choice among three common paths:

Hire for an enduring capability. A permanent hire is usually strongest when the work will span multiple programs, the knowledge should remain inside the company, or the role carries continuing decision authority and cross-functional influence.

Develop internal talent. Development can work when adjacent expertise already exists, the learning curve fits the milestone, and a credible mentor or reviewer can support the transition. The key question is whether the person can become ready before the decision requires them.

Use external support for bounded needs. Consultants, contractors, and specialist partners can be effective when the requirement is temporary, highly specific, or needed faster than a permanent team can be built. Internal ownership must still be explicit, especially when external work will inform a major development or regulatory decision.

Many organizations will use a combination. The important point is to choose the model based on the duration and consequence of the capability, not simply the fastest available option.

Work backward from readiness rather than start date

Even highly experienced scientists need time to learn a new organization, program, and set of working relationships. Specialized searches also require time to define the role, reach the relevant talent market, complete interviews, manage notice periods, and give the new hire enough context to contribute confidently.

That makes the most useful planning question: When must this person be ready to influence the work? From that date, work backward through onboarding, transition time, acceptance, interviews, and search launch. This reveals the latest responsible point to begin, which is often earlier than the date a position first feels urgent.

The same exercise can identify areas where important knowledge or responsibility is concentrated. If one person currently carries much of the program history, regulatory context, and responsibility for interpreting a key analysis, the organization may benefit from broader documentation, knowledge sharing, and team coverage. A resilient plan creates enough depth to support continuity through normal transitions, shifting priorities, and overlapping milestones.

Five questions for the next planning meeting

• Which 2027 pipeline decisions would benefit most from additional capacity or expertise?
• Where would greater capacity help, and where would an additional capability improve readiness?
• Which expertise must remain internal because it carries continuing scientific or regulatory ownership?
• When must each capability be effective, and what lead time does that imply?
• Where is critical knowledge concentrated with one individual or external partner, and how can we strengthen continuity and shared coverage?

Answering these questions will not eliminate every hiring constraint. It will make those constraints visible sooner, when leaders still have options.

Let the pipeline set the priority

The strongest workforce plans do more than describe the team a company would like to have. They show which capabilities protect the next set of scientific and development decisions, how those capabilities will be accessed, and when they must be in place.

For teams in Clinical Pharmacology, Pharmacometrics, DMPK, QSP, PBPK, Bioanalysis, and related quantitative and translational sciences, those connections can be highly specific. A broad labor-market headline will not define the available talent pool, and a job title alone will not define the capability.

Hughes and Associates helps pharmaceutical and biotechnology organizations understand specialized talent markets, clarify high-impact roles, and engage experienced scientific professionals.

Discuss Your 2027 Hiring Priorities

As your organization prepares for upcoming development milestones, Hughes and Associates can help identify specialized scientific talent and support searches aligned with your team’s priorities.

If you are planning to expand your team or anticipate specialized hiring needs in 2027, we would welcome the opportunity to discuss how we can help.

To learn more about our executive and technical search capabilities across the pharmaceutical and biotechnology industries, visit www.haallc.com.

Sources

U.S. Bureau of Labor Statistics – The Employment Situation September 2026 published October 2, 2026

ManpowerGroup  Q4 2026 Employment Outlook Survey  published September 8 2026

Hughes and Associates  Company services and areas of specialization